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Sunday, February 3, 2013 51awhich SbpA monomers that lack significant tertiary structure aggregate rapidly
in solution to form dense protein clusters, which then order into crystalline
sheets.
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The aggregation of amyloidogenic proteins is infamous for being highly cha-
otic, with small variations in conditions leading to large changes in aggregation
rates. We present experimental evidence that the origin of this phenomenom for
a broad variety of amyloidogneic oligomers is related to the critical concentra-
tion for the formation of particular type of prefibrillar oligomer. Using chemical
probes and real time solution NMR, we show that oligomers of this type revers-
ibly form at sharply defined critical concentrations and temperatures in a man-
ner similar to a phase transition. Similarly, the kinetics of fiber formation also
show strong non-linearity near these critical points. For some amyloidogenic
proteins such as IAPP, the pathway of amyloid formation switches as the crit-
ical point is approached, with aggregation initiating at different regions of the
protein above and below the critical point. We also show that part of the effect
of some inhibitors on amyloid aggregation is to abolish or shift the critical con-
centration, and map the interface between monomeric IAPP and Ab and these
aggregates.
261-Pos Board B30
Atomic Resolution Insights into the Aggregation of the Murine Prion
Protein by NMR
Kai A. Schlepckow1,2, Peter Rehbein1,2, Harald Schwalbe1,2.
1Center for Biomolecular Magnetic Resonance, Frankfurt, Germany,
2Institute for Organic Chemistry and Chemical Biology, Frankfurt, Germany.
The aggregation mechanism of the prion protein is known to be complex. It is
highly heterogeneous since multiple oligomeric as well as fibrillar structures
are being populated. It is essential to understand the disease-associated assem-
bly of prion protein monomers into high-molecular-weight polymers in mech-
anistic terms in order to be able to develop tailored therapeutic approaches.
This requires following the aggregation process in detail on the molecular level.
Kinetic methods are especially suited in this respect as the desired mechanistic
information is contained in the kinetic data.
We have investigated the aggregation of the wildtype murine prion protein at
atomic resolution using kinetic two-dimensional (2D) NMR spectroscopy.
We have found amino-acid-specific differences for the decrease in the mono-
mer concentration thereby delineating heterogeneity in the aggregation kinet-
ics. SDS PAGE shows that oligomers of differing size are being formed
which are characterized by extremely high stability. Furthermore, Congo red
dye binding experiments demonstrate that the prion protein assembles into
amyloid-like fibrils. By combining the data acquired by using different methods
we derive a model for the aggregation mechanism of the prion protein. In ad-
dition, we will also present kinetic 2D NMR data on the aggregation of disease-
associated single point mutants of the prion protein such as V180I and E200K
and discuss which aggregation sub-steps are affected by the mutations.
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g-Synuclein is a small intrinsically disordered protein of unknown function that
is usually found in the peripheral nervous system. Phospholipase b2 (PLCb2) is
an important component of the G-protein signaling pathway and its activation
leads to calcium release in cells. These two proteins are both overexpressed in
late stage breast cancer but not in early stage (Stage I and II) or in healthy breast
tissues. We have previously shown that g-synuclein binds strongly to PLCb2
both in-vivo and in-vitro, as demonstrated by immunoprecipitation, immuno-
fluorescence and binding assays. Here, we show that knocking down the ex-
pression of g-synuclein using siRNA, results in a concomitant reduction in
the expression of PLCb2. Here, we also find that reducing the level of g-syn-
uclein in MDA MB 231 cells (which mimics stage 4 breast cancer) causes sig-
nificant changes in cell morphology that indicate a reversion to healthy breast
cell phenotype. Additionally, such reduction of g-synuclein in MDA MB 231cells results in a stronger and faster calcium release in response to G protein
stimulation, corroborating our previous work showing that the binding of g-
synuclein to PLCb2 reduces its activity. We are currently investigating whether
g-synuclein promotes cell proliferation, migration and invasion through its as-
sociation with PLCb2. A peptide inhibitor of the g-synuclein – PLCb2 complex
is presently being tested.
This work was supported by NIH GM053132
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Aggregation of the protein a-synuclein has been associated with Parkinson’s
disease. Here we present a novel way of looking into the aggregation problem,
where we claim that aggregation is correlated with the intramolecular diffusion
dynamics of the polypeptide chain. We hypothesize that the first step of aggre-
gation of disordered proteins, such as a-synuclein, is controlled by the rate of its
backbone reconfiguration. When reconfiguration is fast, bimolecular associa-
tion is not stable, but as reconfiguration slows, association is more stable and
subsequent aggregation is faster. We have tested this hypothesis by investigat-
ing the effects of mutation on the diffusion dynamics of a-synuclein and our
experiments show that mutations enhance or inhibit aggregation based on
how the rate of reconfiguration changes. We have also tested the effects of cer-
tain aggregation inhibitors on a-synuclein. Existing drug screening methods of
such inhibitors are based on their ability to prevent fibrillization as opposed to
initial steps of aggregation. Since our approach probes into the diffusion dy-
namics of the polypeptide chain, it allows us to investigate the inhibitor’s ef-
fects on earlier steps of aggregation, which is believed to be more related to
pathogenesis than the later stages.
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The neural protein a-synuclein (aS) is known to be involved in the develop-
ment of Parkinson’s disease, but specifics about its structure and function re-
main to be determined. aS is intrinsically disordered in solution; however,
upon interacting with lipid membranes, the N-terminus forms an amphipathic
helical structure along the membrane interface while the C-terminus remains
unstructured in solution. A thiocyanate probe group has been covalently at-
tached to a number of single-cysteine variants of aS, and IR signals were ob-
tained to investigate the environment and local dynamics of the N-terminal
segment of aS. The frequency of the aliphatic CN absorption band of the probe
group in the IR spectrum is sensitive to the degree of hydration of the probe,
indicating its orientation with respect to the bilayer, while the bandwidth of
the CN stretching absorption is sensitive to the ps solvent dynamics surround-
ing the probe and can report on local rigidification of the structure. Spectra of
aS in a number of different lipid systems have provided new information re-
garding the dynamics and structure of the lipid-bound conformation, including
direct evidence for a partially-bound structure in which only the beginning of
the N-terminus is associated with the lipid membrane.
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Aggregation of the neuronal protein alpha-synuclein (aS) is implicated in the
pathology of Parkinson’s disease (PD). The causative role of aS in disease is
further supported by rare mutations in or gene multiplications of aS that are re-
sponsible for early-onset PD. While the link between aS and PD is well estab-
lished, the physiological roles of aS are not well-understood. A likely function
has been suggested in regulation of synaptic vesicle fusion and maintenance of
the synaptic vesicle pool, with recent work indicating a direct interaction be-
tween aS and SNARE proteins. Here, using an in vitro fusion assay, we inves-
tigate the mechanism by which aS modulates SNARE-mediated vesicle fusion.
We find that aS inhibits fusion in a manner that correlates with its affinity for
the lipid bilayer. Moreover, we do not detect interactions between aS and
SNARE proteins in a variety of assays. Although we cannot completely elim-
inate the possibility of weak or transient interactions with SNARE proteins, our
results suggest that aS inhibits fusion through its interaction with the lipid
membrane rather than SNARE components.
